

Grants to Oxford University for any Clinical Trial Service Unit (CTSU) trials or other commercially-funded research over the past 20 years
(but excluding CTSU core support from MRC, CR-UK and BHF for these and other studies, as well as other non-commercially funded research)

- ACST-2 trial of carotid procedures (2007-ongoing)
 - BUPA: £60K
 - NHS-HTA: £200K
- ASCEND trial of aspirin and fish oils (2004-ongoing)
 - British Heart Foundation: £2.7M
 - Abbott/Solvay: £2.0M plus drug supply
 - Bayer: £1.7M plus drug supply
- ATLAS trial of tamoxifen duration (1997-ongoing)
 - US Army: \$1.6M
 - AstraZeneca: £1.0M plus drug supply
- ATLAS trial of psychosis treatment (2011-ongoing)
 - NHS-HTA: £500K
- BEST-D pilot trial of vitamin D (2012-ongoing)
 - British Heart Foundation: £150K
 - Tishcon: free drug supply only
- CCS-2 trial of metoprolol and clopidogrel (1999-2005)
 - AstraZeneca: £1.1M plus drug supply
 - Sanofi: £1.1M plus drug supply
- China Kadoorie Biobank (2002-ongoing)
 - Kadoorie Trust: £4.7M
 - Medical Research Council: £1.3M
 - Wellcome Trust: £2.5M
 - AstraZeneca: \$300K
 - GlaxoSmithKline: £2.2M
 - Merck: £200K
- Elinogrel feasibility trial (2010-2011)
 - Novartis: £500K
- Establishing Fuwai-Oxford research centre (2010-ongoing)
 - Merck: £1.1M
- Heart Protection Study (1993-2002)
 - British Heart Foundation: £1.2M
 - Medical Research Council £9.6M
 - Merck: £5.5M plus drug supply
 - Roche: £5.5M plus drug supply
- Heart Protection Study follow-up studies (2003-ongoing)
 - BHF: £350K
 - Merck: £1.2M
 - GlaxoSmithKline: \$400K
 - Liposcience: £50K
- HPS2-THRIVE trial of niacin/laropiprant (2005-ongoing)
 - Merck: £53M plus drug supply
- HPS3/TIMI55-REVEAL trial of anacetrapib (2010-ongoing)
 - Merck: £96M plus drug supply
- Leukaemia trials (2010-ongoing)
 - Cancer Research UK: £200K

Medical Research Council: £2.8M
Kay Kendall Leukaemia Fund: £200K
Pfizer Innovation Award (2004)
Pfizer: £50K to CTSU for unrestricted research
PROCARDIS genetic study (1998-2011)
European Union: £2.0M
AstraZeneca: £1.7M
SEARCH trial of simvastatin dose (1997-2010)
Merck: £22.7M plus drug supply
SHARP trial of simvastatin/ezetimibe (2002-2013)
Merck/Schering: £40M plus drug supply
STICS trial of rosuvastatin (2011-2014)
British Heart Foundation: £225K
European Union: £15K
AstraZeneca: \$100K
3-C trial of transplant rejection (2009-2017)
NHS Blood Transfusion: £250K
Pfizer: £500K
Novartis: £350K

Patents: Myopathy-related genetic variant; licensed by Oxford University to Boston Heart Diagnostics; all personal income waived in favour of the University and CTSU to support research

NOTE: The CTSU conducts, analyses and interprets its clinical trials and other research independently of industry and other funders, with the datasets held by the CTSU rather than by the funders. In accordance with CTSU's long-term policy (see attached), honoraria, consultancy or other payments have not been received directly or indirectly from industry, either personally by Professor Collins or by the University (except for reimbursement of travel and accommodation costs for taking part in relevant scientific meetings).